BioPharma Dive December 17, 2025
Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes can sidestep issues seen with traditional gene therapy technology.
Addition Therapeutics has emerged from stealth with $100 million in hand to develop new types of gene therapies that might work against rare as well as chronic diseases.
Spun out of research at the University of California, Berkeley, the startup is pursuing genetic medicines intended to work differently from existing approaches and, in the process, overcome some of their key limitations.
The gene therapies and gene editing treatments that have come to market so far are essentially blunt tools. Gene therapies typically work by delivering into cells genetic cargo to...
Today's Sponsors
Today's Sponsor